ARTICLE | Clinical News
Vectura discontinues asthma therapy after Phase III miss
November 30, 2018 8:34 PM UTC
Vectura Group plc (LSE:VEC) said it will discontinue development of VR475 after both doses of the compound missed the primary endpoint in a Phase III trial to treat severe uncontrolled asthma.
Both twice-daily 0.5 and 1 mg VR475, given for one year, failed to reduce annualized rate of clinically significant exacerbations vs. placebo. The double-blind, international trial enrolled 713 patients. ...
BCIQ Company Profiles